Stockreport

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO [Read more]